Every 10-Q that Nutex Health Inc (NUTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUTX filings page.
Nutex Health Inc. reported Q2 and first-half 2026 results showing a sharp swing to profitability. Net income attributable to Nutex Health was 65,842 (thousand) for the quarter and 112,649 (thousand) for the first six months, compared with a loss of 17,697 (thousand) and income of 3,520 (thousand) a year earlier. The improvement reflects much lower stock-based compensation and a 52,319 (thousand) reduction in contract services expense from amended arbitration cost estimates related to HaloMD and lower federal IDR fees, which increased net income attributable to Nutex by 25.0 million.
Total revenue declined to 210,752 (thousand) for Q2 and 427,237 (thousand) year‑to‑date from 243,985 (thousand) and 455,774 (thousand) in 2025, driven mainly by lower hospital division revenue, while gross profit remained strong. Cash and cash equivalents rose to 205,208 (thousand), supported by 109,718 (thousand) of operating cash flow, even as the company used 50,688 (thousand) for stock repurchases and share retirements and carried 39,899 (thousand) of debt and 49,668 (thousand) of accrued arbitration expenses. Operations remain closely tied to the evolving No Surprises Act independent dispute resolution framework, with complex reimbursement dynamics and ongoing regulatory and legal developments.
Nutex Health Inc. reported strong Q1 2026 results with higher profit and cash generation while continuing heavy use of arbitration under the No Surprises Act.
Total revenue was $216.5 million, up modestly from $211.8 million a year earlier, driven mainly by the hospital division’s $207.6 million. Net income rose to $62.8 million, with $46.8 million attributable to Nutex, more than double the prior-year $21.2 million. Basic earnings per share increased to $6.70, and operating income was $81.3 million.
Operating cash flow reached $75.5 million, lifting cash, cash equivalents and restricted cash to $210.6 million at March 31, 2026. The company spent $31.7 million on stock repurchases and retired 200,444 shares, while also settling certain disputes with former doctor owners and retiring additional shares.
Nutex’s business remains highly exposed to out-of-network reimbursement and arbitration. Arbitration-related costs for hospital and professional services were $46.1 million in the quarter, and accrued arbitration expenses increased to $56.8 million, reflecting the scale and complexity of the Independent Dispute Resolution process.
Nutex Health Inc. reported a sharp turnaround for the quarter ended September 30, 2025, with total revenue of $267.8 million versus $78.8 million a year earlier and net income attributable to Nutex of $55.4 million compared with a loss of $8.8 million. The hospital division drove most of the growth, generating $260.2 million in quarterly revenue and $700.5 million for the first nine months, up from $199.4 million in the prior-year period, while population health revenue was stable.
For the first nine months of 2025, total revenue rose to $723.6 million from $222.3 million, and net income attributable to Nutex improved to $59.0 million from a loss of $9.5 million. Basic earnings per share were $8.27 for the quarter and $9.63 year-to-date. Cash and cash equivalents increased to $166.0 million from $40.6 million at December 31, 2024, supported by $177.7 million of net cash from operating activities. Results include substantial non-cash stock-based compensation of $119.6 million year-to-date, largely tied to obligations for under-construction and ramping hospitals, and growing arbitration-related accruals under the No Surprises Act.
Nutex Health Inc. reports sharply higher results for the quarter ended June 30, 2025, with total revenue rising to $243.985 million from $76.082 million a year earlier, driven mainly by hospital division revenue of $236.302 million. Gross profit increased to $124.924 million, and operating income climbed to $33.679 million. However, heavy stock-based compensation of $78.747 million, largely tied to obligations for under-construction and ramping hospitals, led to a net loss attributable to Nutex of $17.697 million for the quarter, even though consolidated net income was $16.144 million due to substantial earnings allocated to noncontrolling interests. For the first six months of 2025, revenue reached $455.774 million and net income attributable to Nutex was $3.520 million, with cash and cash equivalents increasing to $96.733 million. The company also recorded $68.785 million of accrued arbitration expenses related to No Surprises Act reimbursement disputes and disclosed new legal challenges over stock issuance terms.
Nutex Health Inc. filed an amended Q1 2025 report to restate its financial statements and internal control conclusions. The company reclassified $20.7 million of non‑cash stock‑based compensation obligations tied to under‑construction and ramping hospitals from equity to liabilities, and made additional reclassifications including $3.5 million of related‑party payables to equity, $2.9 million from cash to restricted short‑term investments, and a $2.4 million income tax accrual adjustment. As a result, total liabilities as of March 31 2025 increased by $19.6 million (4.0%), equity decreased by $19.6 million (7.1%), and net income for the quarter rose by $6.6 million (14.9%) to $50.8 million. Basic earnings per share increased to $3.74 and diluted earnings per share to $3.33. The company states these changes are non‑cash and did not materially affect revenue, liquidity, debt, operating cash flow, adjusted EBITDA or patient volumes. Management concluded a previously identified material weakness in internal control over financial reporting remains unresolved as of March 31 2025, and has engaged an accounting firm to help remediate it.